Peptides are everywhere in skincare and longevity circles, but the science behind them is a mixed bag. A dermatologist-scientist breaks down which topical peptides have solid clinical backing — and which systemic uses are outpacing the evidence. The bottom line: some work, some are promising, and some carry real safety risks that the wellness industry isn't talking about.
Peptides are being marketed as fixes for everything from wrinkles to aging itself, but a rigorous look at the evidence reveals a wide spectrum — from well-studied topical agents to largely unproven systemic "longevity stacks." Dermatologist-scientist Dr. Macrene Alexiades breaks it all down, covering collagen-building peptides, neuromodulatory ("Botox-like") peptides, GLP-1 receptor agonists, and emerging longevity peptides like Epithalon and MOTS-c.
On the topical side, palmitoyl pentapeptide-4 (Matrixyl) and GHK-Cu have the strongest clinical evidence, with randomized trials showing real improvements in wrinkle depth and skin density. Neuromodulatory peptides like Argireline offer modest, measurable effects — but are nowhere near a substitute for botulinum toxin. The bigger concern is the growing trend of patients injecting or orally consuming peptides originally developed only for topical use, with no systemic safety data to support those routes of administration.
Key Takeaways:
Why it matters: Patients are increasingly self-administering compounded peptide injectables based on wellness trends, not clinical evidence. Dermatologists are uniquely positioned to counsel on both the real benefits and the understudied risks — and that distinction is critical for informed consent.
